BRIEF-Agios announces new clinical data from dose-escalation portion of Phase 1 trial of single agent AG-120 showing durable molecular responses in patients with advanced Hematologic Malignancies
* For relapsed/refractory acute myeloid leukemia patients,
overall response rate of 33% ,complete remission rate of 16%
No comments:
Post a Comment